Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions

Isabella C. Glitza; Keiran S.M. Smalley; Priscilla K. Brastianos; Michael A. Davies; Ian McCutcheon; James K.C. Liu; Kamran A. Ahmed; John A. Arrington; Brittany R. Evernden; Inna Smalley; Zeynep Eroglu; Nikhil Khushalani; Kim Margolin; Harriet Kluger; Michael B. Atkins; Hussein Tawbi; Adrienne Boire; Peter Forsyth

doi:10.1111/pcmr.12861

Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions

Isabella C. Glitza, Keiran S.M. Smalley, Priscilla K. Brastianos, Michael A. Davies, Ian McCutcheon, James K.C. Liu, Kamran A. Ahmed, John A. Arrington, Brittany R. Evernden, Inna Smalley, Zeynep Eroglu, Nikhil Khushalani, Kim Margolin, Harriet Kluger, Michael B. Atkins, Hussein Tawbi, Adrienne Boire, Peter Forsyth

Research output: Contribution to journal › Review article › peer-review

37 Scopus citations

Abstract

In February 2018, the Melanoma Research Foundation and the Moffitt Cancer Center hosted the Second Summit on Melanoma Central Nervous System Metastases in Tampa, Florida. The meeting included investigators from multiple academic centers and disciplines. A consensus summary of the progress and challenges in melanoma parenchymal brain metastases was published (Eroglu et al., Pigment Cell & Melanoma Research, 2019, 32, 458). Here, we will describe the current state of basic, translational, clinical research, and therapeutic management, for melanoma patients with leptomeningeal disease. We also outline key challenges and barriers to be overcome to make progress in this deadly disease.

Original language	English (US)
Pages (from-to)	527-541
Number of pages	15
Journal	Pigment Cell and Melanoma Research
Volume	33
Issue number	4
DOIs	https://doi.org/10.1111/pcmr.12861
State	Published - Jul 1 2020

Keywords

intrathecal therapy
leptomeningeal carcinomatosis
leptomeningeal disease
melanoma
neoplastic meningitis

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology
Oncology
Dermatology

Access to Document

10.1111/pcmr.12861

Cite this

Glitza, I. C., Smalley, K. S. M., Brastianos, P. K., Davies, M. A., McCutcheon, I., Liu, J. K. C., Ahmed, K. A., Arrington, J. A., Evernden, B. R., Smalley, I., Eroglu, Z., Khushalani, N., Margolin, K., Kluger, H., Atkins, M. B., Tawbi, H., Boire, A., & Forsyth, P. (2020). Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions. Pigment Cell and Melanoma Research, 33(4), 527-541. https://doi.org/10.1111/pcmr.12861

Glitza, IC, Smalley, KSM, Brastianos, PK, Davies, MA , McCutcheon, I, Liu, JKC, Ahmed, KA, Arrington, JA, Evernden, BR, Smalley, I, Eroglu, Z, Khushalani, N, Margolin, K, Kluger, H, Atkins, MB, Tawbi, H, Boire, A & Forsyth, P 2020, 'Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions', Pigment Cell and Melanoma Research, vol. 33, no. 4, pp. 527-541. https://doi.org/10.1111/pcmr.12861

@article{1a288cd3e6d04ecd99b00fec2a37d679,

title = "Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions",

abstract = "In February 2018, the Melanoma Research Foundation and the Moffitt Cancer Center hosted the Second Summit on Melanoma Central Nervous System Metastases in Tampa, Florida. The meeting included investigators from multiple academic centers and disciplines. A consensus summary of the progress and challenges in melanoma parenchymal brain metastases was published (Eroglu et al., Pigment Cell & Melanoma Research, 2019, 32, 458). Here, we will describe the current state of basic, translational, clinical research, and therapeutic management, for melanoma patients with leptomeningeal disease. We also outline key challenges and barriers to be overcome to make progress in this deadly disease.",

keywords = "intrathecal therapy, leptomeningeal carcinomatosis, leptomeningeal disease, melanoma, neoplastic meningitis",

author = "Glitza, {Isabella C.} and Smalley, {Keiran S.M.} and Brastianos, {Priscilla K.} and Davies, {Michael A.} and Ian McCutcheon and Liu, {James K.C.} and Ahmed, {Kamran A.} and Arrington, {John A.} and Evernden, {Brittany R.} and Inna Smalley and Zeynep Eroglu and Nikhil Khushalani and Kim Margolin and Harriet Kluger and Atkins, {Michael B.} and Hussein Tawbi and Adrienne Boire and Peter Forsyth",

note = "Publisher Copyright: {\textcopyright} 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd",

year = "2020",

month = jul,

day = "1",

doi = "10.1111/pcmr.12861",

language = "English (US)",

volume = "33",

pages = "527--541",

journal = "Pigment Cell and Melanoma Research",

issn = "1755-1471",

publisher = "Wiley-Blackwell",

number = "4",

}

TY - JOUR

T1 - Leptomeningeal disease in melanoma patients

T2 - An update to treatment, challenges, and future directions

AU - Glitza, Isabella C.

AU - Smalley, Keiran S.M.

AU - Brastianos, Priscilla K.

AU - Davies, Michael A.

AU - McCutcheon, Ian

AU - Liu, James K.C.

AU - Ahmed, Kamran A.

AU - Arrington, John A.

AU - Evernden, Brittany R.

AU - Smalley, Inna

AU - Eroglu, Zeynep

AU - Khushalani, Nikhil

AU - Margolin, Kim

AU - Kluger, Harriet

AU - Atkins, Michael B.

AU - Tawbi, Hussein

AU - Boire, Adrienne

AU - Forsyth, Peter

PY - 2020/7/1

Y1 - 2020/7/1

N2 - In February 2018, the Melanoma Research Foundation and the Moffitt Cancer Center hosted the Second Summit on Melanoma Central Nervous System Metastases in Tampa, Florida. The meeting included investigators from multiple academic centers and disciplines. A consensus summary of the progress and challenges in melanoma parenchymal brain metastases was published (Eroglu et al., Pigment Cell & Melanoma Research, 2019, 32, 458). Here, we will describe the current state of basic, translational, clinical research, and therapeutic management, for melanoma patients with leptomeningeal disease. We also outline key challenges and barriers to be overcome to make progress in this deadly disease.

AB - In February 2018, the Melanoma Research Foundation and the Moffitt Cancer Center hosted the Second Summit on Melanoma Central Nervous System Metastases in Tampa, Florida. The meeting included investigators from multiple academic centers and disciplines. A consensus summary of the progress and challenges in melanoma parenchymal brain metastases was published (Eroglu et al., Pigment Cell & Melanoma Research, 2019, 32, 458). Here, we will describe the current state of basic, translational, clinical research, and therapeutic management, for melanoma patients with leptomeningeal disease. We also outline key challenges and barriers to be overcome to make progress in this deadly disease.

KW - intrathecal therapy

KW - leptomeningeal carcinomatosis

KW - leptomeningeal disease

KW - melanoma

KW - neoplastic meningitis

UR - http://www.scopus.com/inward/record.url?scp=85078781932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85078781932&partnerID=8YFLogxK

U2 - 10.1111/pcmr.12861

DO - 10.1111/pcmr.12861

M3 - Review article

C2 - 31916400

AN - SCOPUS:85078781932

SN - 1755-1471

VL - 33

SP - 527

EP - 541

JO - Pigment Cell and Melanoma Research

JF - Pigment Cell and Melanoma Research

IS - 4

ER -

Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this